This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions
Risk of fatal ICH with alteplase for stroke
{
"resourceType" : "Evidence",
"id" : "example-stroke-alteplase-fatalICH",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n \n <p>\n "Risk of fatal ICH with alteplase for stroke" is a univariate risk estimate.\n </p>\n\t\n </div>"
},
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "cds"
}],
"url" : "http://hl7.org/fhir/Evidence/example-stroke-alteplase-fatalICH",
"identifier" : [{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.10.1"
}],
"name" : "RiskOfFatalICHWithAlteplaseForStroke",
"title" : "Risk of fatal ICH with alteplase for stroke",
"status" : "draft",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [{
"telecom" : [{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}]
}],
"relatedArtifact" : [{
"type" : "citation",
"label" : "Emberson 2014",
"display" : "Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.",
"citation" : "Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al;Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014 Nov 29;384(9958):1929-35 PMID 25106063",
"document" : {
"url" : "https://doi.org/10.1016/S0140-6736(14)60584-5"
}
}],
"description" : "2.7% incidence of fatal intracranial hemorrhage within 7 days with alteplase in patients with acute ischemic stroke",
"variableDefinition" : [{
"variableRole" : "population",
"observed" : {
"reference" : "Group/Emberson-2014-IPD-MA-Alteplase-Cohort",
"type" : "Group",
"display" : "Emberson 2014 IPD-MA Alteplase Cohort"
},
"intended" : {
"reference" : "Group/AcuteIschemicStrokeTreatedWithAlteplase",
"type" : "Group",
"display" : "adults with acute ischemic stroke treated with alteplase"
}
},
{
"variableRole" : "outcome",
"observed" : {
"reference" : "EvidenceVariable/example-fatal-ICH-in-7-days",
"type" : "EvidenceVariable",
"display" : "fatal ICH"
},
"intended" : {
"reference" : "EvidenceVariable/example-fatal-ICH-in-7-days",
"type" : "EvidenceVariable",
"display" : "fatal ICH"
}
}],
"synthesisType" : {
"coding" : [{
"system" : "http://terminology.hl7.org/CodeSystem/synthesis-type",
"code" : "IPD-MA",
"display" : "individual patient data meta-analysis"
}]
},
"studyDesign" : [{
"coding" : [{
"system" : "http://hl7.org/fhir/study-design",
"code" : "SEVCO:01003",
"display" : "randomized assignment"
}]
}],
"statistic" : [{
"statisticType" : {
"coding" : [{
"system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
"code" : "C44256",
"display" : "Proportion"
}]
},
"quantity" : {
"value" : 0.026835741669
},
"numberOfEvents" : 91,
"sampleSize" : {
"numberOfStudies" : 9,
"numberOfParticipants" : 3391
}
}]
}
Usage note: every effort has been made to ensure that the
examples are correct and useful, but they are not a normative part
of the specification.